top of page

Library Bookshelves

ATXA PUBLICATIONS

Journal Publications

Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial

Frontiers in Pharmacology - December 2023

The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload

Frontiers in Cardiovascular Medicine - December 2022

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

European Journal of Pharmacology - December 2020

Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension

Cardiovascular Research - July 2018

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

BMC Pulmonary Medicine - April 2020

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

Experimental and Molecular Pathology - October 2019

Conference Posters

A Phase I Clinical Trial Assessing the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of NTP42:KVA4, a Novel Thromboxane Receptor Antagonist, in Healthy Subjects

American Thoracic Society International Conference 2023 - Washington, DC, USA - May 2023

NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function

European Respiratory Society International Congress 2022 - Barcelona, Spain - September 2022

The thromboxane receptor antagonist NTP42 improves haemodynamics, inhibits remodelling, and restores function within the cardiopulmonary system in preclinical pulmonary arterial hypertension models

European Society of Cardiology Congress 2021 - The Digital Experience - August 2021

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

European Respiratory Society International Congress - Madrid, Spain - September/October 2019

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the Sugen/hypoxia-induced model of pulmonary arterial hypertension

European Society of Cardiology World Congress - Paris, France - August/September 2019

bottom of page